
Sofinnova leads £15m round for Green Biologics
Sofinnova Partners has led a £15.4m series-B funding round for Green Biologics, a UK-based chemicals producer, alongside Hong Kong-based Swire Pacific and several existing investors.
Capricorn Venture Partners, Oxford Capital Partners (OCP), Morningside Ventures and Convergince Holdings reinvested in Green Biologics as part of the round.
The fresh funding will be used by the company to finance the eventual launch of its first commercial production facility in the US, due to take place in 2016.
Previous funding
In November 2007, OCP led a £1.6m series-A round for the company, with participation from angel investors and Carbon Trust Investments. Prior to this round, Green Biologics had completed a couple of seed funding rounds with a combined value of around £370,000, according to its website.
In February 2009, the company received a further £1m from OCP, Carbon Trust and Morningside. This was followed in May 2010 with OCP, Capricorn, Carbon Trust and Morningside committing £4.9m to Green Biologics.
In May last year, Capricorn, OCP and Morningside injected a further £3.2m into the company. The three firms then provided an additional £2m to the company in July this year.
Company
Founded in 2003, Green Biologics is headquartered in Abingdon with an additional office in Ashland, Virginia, and a laboratory located in Columbus, Ohio. The company employs 40 staff.
Green Biologics has developed fermentation technology for the production of renewable C4 chemicals, with a core focus on the manufacturing of n-butanol. The chemical n-butanol is used in food and drink, household cleaning products, paints, adhesives, inks, plastics and pharmaceuticals. The global n-butanol market exceeds $6bn, according to Green Biologics.
The company produces renewable n-butanol from feedstocks such as grasses, corn, sugar beets and sugar cane. By using feedstocks, the company has access to lower-cost sugars.
People
Sean Sutcliffe is the CEO of Green Biologics. The company's board of directors includes Capricorn senior investment manager Claude Stoufs, OCP operating partner David Brister and Morningside's Reenie McCarthy. Denis Lucquin is a managing partner at Sofinnova.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater